SunTrust Banks began coverage on shares of Endo International (NASDAQ:ENDP) (TSE:ENL) in a note issued to investors on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $13.00 price target on the stock. SunTrust Banks’ price objective suggests a potential upside of 48.06% from the company’s current price.
A number of other analysts have also recently commented on ENDP. Zacks Investment Research cut Endo International from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 14th. ValuEngine upgraded Endo International from a “sell” rating to a “hold” rating in a research report on Tuesday, March 12th. JPMorgan Chase & Co. reduced their price target on Endo International from $16.00 to $10.00 and set a “neutral” rating for the company in a research report on Monday. BidaskClub cut Endo International from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th. Finally, Canaccord Genuity set a $17.00 price target on Endo International and gave the stock a “buy” rating in a research report on Friday, March 8th. Fifteen investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Endo International has a consensus rating of “Hold” and an average target price of $15.17.
Endo International stock traded up $0.01 during mid-day trading on Tuesday, reaching $8.78. 21,832 shares of the stock traded hands, compared to its average volume of 4,381,593. The stock has a market cap of $1.93 billion, a PE ratio of 3.04 and a beta of 1.21. Endo International has a 12-month low of $5.27 and a 12-month high of $18.50.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. LS Investment Advisors LLC bought a new position in Endo International during the fourth quarter valued at approximately $59,000. Oregon Public Employees Retirement Fund bought a new position in Endo International during the fourth quarter valued at approximately $76,000. First Quadrant L P CA bought a new position in Endo International during the fourth quarter valued at approximately $92,000. Neuburgh Advisers LLC boosted its stake in Endo International by 13.9% during the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after buying an additional 3,036 shares during the last quarter. Finally, Neuberger Berman Group LLC bought a new position in Endo International during the third quarter valued at approximately $202,000. 92.40% of the stock is owned by hedge funds and other institutional investors.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.